Abstract
Attention deficit hyperactivity disorder (ADHD) is a long recognized and common childhood disorder. ADHD adolescents tend to encounter more difficulties in school and peer relationships, whereas ADHD adults have more occupational and interpersonal difficulties. However, with the treatment of central nervous system (CNS) stimulants, 10-20 % of the patients still remain poor responders to treatment. Among hypotheses for ADHD, dysfunction of N-methyl-D-aspartate (NMDA)-type glutamate receptors has recently been suggested by accumulating genetic and animal studies. This article systemically reviews evidence supporting NMDA dysfunction as a potential ADHD pathogenesis from perspectives of neurodevelopment, attentional circuitry, and impulse inhibition. The review also addresses the development of novel treatments for ADHD via modulation of glutamatergic system, particularly the NMDA/glycine site. These so-called NMDA enhancers may provide a new treatment option for patients with ADHD.
Keywords: ADHD, NMDA, attention deficit hyperactivity disorder, glycine, glutamate, treatment.
Current Pharmaceutical Design
Title:Attention Deficit Hyperactivity Disorder and N-methyl-D-aspartate (NMDA) Dysregulation
Volume: 20 Issue: 32
Author(s): Jane Pei-Chen Chang, Hsien-Yuan Lane and Guochuan E. Tsai
Affiliation:
Keywords: ADHD, NMDA, attention deficit hyperactivity disorder, glycine, glutamate, treatment.
Abstract: Attention deficit hyperactivity disorder (ADHD) is a long recognized and common childhood disorder. ADHD adolescents tend to encounter more difficulties in school and peer relationships, whereas ADHD adults have more occupational and interpersonal difficulties. However, with the treatment of central nervous system (CNS) stimulants, 10-20 % of the patients still remain poor responders to treatment. Among hypotheses for ADHD, dysfunction of N-methyl-D-aspartate (NMDA)-type glutamate receptors has recently been suggested by accumulating genetic and animal studies. This article systemically reviews evidence supporting NMDA dysfunction as a potential ADHD pathogenesis from perspectives of neurodevelopment, attentional circuitry, and impulse inhibition. The review also addresses the development of novel treatments for ADHD via modulation of glutamatergic system, particularly the NMDA/glycine site. These so-called NMDA enhancers may provide a new treatment option for patients with ADHD.
Export Options
About this article
Cite this article as:
Chang Pei-Chen Jane, Lane Hsien-Yuan and Tsai E. Guochuan, Attention Deficit Hyperactivity Disorder and N-methyl-D-aspartate (NMDA) Dysregulation, Current Pharmaceutical Design 2014; 20 (32) . https://dx.doi.org/10.2174/1381612819666140110115227
DOI https://dx.doi.org/10.2174/1381612819666140110115227 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Regulation of Mitochondrial Function and its Impact in Metabolic Stress
Current Medicinal Chemistry Applications of Lipid based Formulation Technologies in the Delivery of Biotechnology-based Therapeutics
Current Pharmaceutical Biotechnology The Delicate Equilibrium between Oxidants and Antioxidants in Brain Glioma
Current Neuropharmacology Neuroprotection & Mechanism of Ethanol in Stroke and Traumatic Brain Injury Therapy: New Prospects for an Ancient Drug
Current Drug Targets Selective VEGFR Inhibitors for Anticancer Therapeutics in Clinical Use and Clinical Trials
Current Pharmaceutical Design Anti-cancer Research on Arnebiae radix-derived Naphthoquinone in Recent Five Years
Recent Patents on Anti-Cancer Drug Discovery Editorial [Hot Topic: Oncolytic viruses]
Current Pharmaceutical Biotechnology Mechanisms of Oxidative Glutamate Toxicity: The Glutamate/Cystine Antiporter System xc¯ as a Neuroprotective Drug Target
CNS & Neurological Disorders - Drug Targets Anticancer Drug Design Using Scaffolds of β-Lactams, Sulfonamides, Quinoline, Quinoxaline and Natural Products. Drugs Advances in Clinical Trials
Current Medicinal Chemistry Preparation of Doughnut-like Nanocomposite Colloidal Crystal Particles with Enhanced Light Diffraction Using Drying Self-assembly Method
Current Nanoscience Immunologic Diseases and Brain Tumors
Inflammation & Allergy - Drug Targets (Discontinued) EDITORIAL [Hot topic: RAS - A Central Feature in Cancer Targeted Therapy (Guest Editor: Balazs Gyorffy)
Current Cancer Drug Targets Endothelial Cell Heterogeneity: A Developmental Biologist’s Perspective
Current Angiogenesis (Discontinued) Advances in Anticancer Antibody-Drug Conjugates and Immunotoxins
Recent Patents on Anti-Cancer Drug Discovery Nongenomic Actions of Thyroid Hormones: Every why has a Wherefore
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Metabolite Quantification in Tumours by Magnetic Resonance Spectroscopy: Objectives, Results and Perspectives
Current Medical Imaging Transmembrane Protein 166 and its Significance
Protein & Peptide Letters Receptor Mediated Tumor Targeting: An Emerging Approach for Cancer Therapy
Current Drug Delivery Neurodegeneration in the Brain Tumor Microenvironment: Glutamate in the Limelight
Current Neuropharmacology Boron Containing Macromolecules and Nanovehicles as Delivery Agents for Neutron Capture Therapy†
Anti-Cancer Agents in Medicinal Chemistry